Genervon Biopharmaceuticals, LLC
Genervon is a clinical-stage biopharmaceutical company dedicated to pioneering neuroprotection and regeneration for neurodegenerative diseases. They focus on multi-target drug development, with GM6 as a key peptide that crosses the blood-brain barrier and modulates multiple pathways to treat conditions like ALS, Parkinson's, Alzheimer's, and MS. With a history of extensive research and patents, Genervon aims to develop therapies that address the complex pathology of neurological disorders.
Industries
Nr. of Employees
small (1-50)
Genervon Biopharmaceuticals, LLC
1055 E. Colorado Blvd., Suite 500, Pasadena, CA 91106 USA
Patents
Methods of using GM604 in modulating ALS disease biomarkers leading to prognosis and therapeutic treatment for ALS disease
US-10632169-B2
View Details
Methods of using GM604 in modulating ALS disease biomarkers leading to prognosis and therapeutic treatment for ALS disease
US-10632169-B2
View DetailsProducts
Clinical‑stage short peptide CNS therapeutic candidate (6‑amino‑acid cell‑penetrating peptide)
A 6‑amino‑acid, cationic, cell‑penetrating peptide analog of an endogenous developmental neurotrophic regulator developed as a pleiotropic CNS therapeutic candidate intended to modulate multiple disease pathways and biomarkers across neurodegenerative indications.
Clinical‑stage short peptide CNS therapeutic candidate (6‑amino‑acid cell‑penetrating peptide)
A 6‑amino‑acid, cationic, cell‑penetrating peptide analog of an endogenous developmental neurotrophic regulator developed as a pleiotropic CNS therapeutic candidate intended to modulate multiple disease pathways and biomarkers across neurodegenerative indications.
Services
In vivo efficacy studies across validated CNS models with behavioral, histological and biomarker endpoints (ALS SOD1-G93A, APP/ΔPS1, h‑Tau, MCAO stroke, MPTP/6‑OHDA PD, EAE MS, spinal cord injury).
Genome‑scale transcriptional profiling (RNA‑seq), receptor screening and pathway mapping to identify drug‑responsive genes, receptors and signaling cascades relevant to neuroprotection and regeneration.
Design and conduct of Phase 1 safety studies and Phase 2A randomized, double‑blind, placebo‑controlled trials with integrated biomarker programs for CNS indications.
GMP‑compatible solid‑phase peptide synthesis and formulation support with validated long‑term stability data at specified storage conditions.
In vivo efficacy studies across validated CNS models with behavioral, histological and biomarker endpoints (ALS SOD1-G93A, APP/ΔPS1, h‑Tau, MCAO stroke, MPTP/6‑OHDA PD, EAE MS, spinal cord injury).
Genome‑scale transcriptional profiling (RNA‑seq), receptor screening and pathway mapping to identify drug‑responsive genes, receptors and signaling cascades relevant to neuroprotection and regeneration.
Design and conduct of Phase 1 safety studies and Phase 2A randomized, double‑blind, placebo‑controlled trials with integrated biomarker programs for CNS indications.
GMP‑compatible solid‑phase peptide synthesis and formulation support with validated long‑term stability data at specified storage conditions.
Expertise Areas
- Neurodegenerative disease therapeutics (ALS, AD, PD, MS, stroke, SCI)
- Peptide therapeutic design and CMC for CNS delivery
- Preclinical in vitro and in vivo CNS efficacy testing
- Translational biomarker development and quantification
Key Technologies
- Solid‑phase peptide synthesis (GMP-compatible)
- Biomimetic HPLC for brain:plasma and protein binding estimation
- RNA‑seq transcriptomics
- DNA microarray and PCR array assays